ITP, interrupted

Abstract

The study by Khellaf et al. in this issue of Blood suggests that the use of romiplostim outside a formal clinical trial setting can safely produce a sustained clinical benefit in 65% of patients with chronic or refractory primary immune thrombocytopenia (ITP), particularly those who present with less severe bleeding manifestations.